- Home
- FUTU vs BIO Comparison
FUTU vs BIO Comparison
Compare FUTU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUTU
- BIO
- Stock Information
- Founded
- FUTU 2011
- BIO 1952
- Country
- FUTU Hong Kong
- BIO United States
- Employees
- FUTU N/A
- BIO N/A
- Industry
- FUTU Investment Bankers/Brokers/Service
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- FUTU Finance
- BIO Industrials
- Exchange
- FUTU Nasdaq
- BIO Nasdaq
- Market Cap
- FUTU N/A
- BIO 6.0B
- IPO Year
- FUTU 2019
- BIO N/A
- Fundamental
- Price
- FUTU $121.50
- BIO $251.56
- Analyst Decision
- FUTU Strong Buy
- BIO Strong Buy
- Analyst Count
- FUTU 4
- BIO 4
- Target Price
- FUTU $136.23
- BIO $324.25
- AVG Volume (30 Days)
- FUTU 1.9M
- BIO 407.6K
- Earning Date
- FUTU 08-19-2025
- BIO 07-31-2025
- Dividend Yield
- FUTU 1.60%
- BIO N/A
- EPS Growth
- FUTU 58.31
- BIO N/A
- EPS
- FUTU 6.00
- BIO N/A
- Revenue
- FUTU $1,788,948,850.00
- BIO $2,541,100,000.00
- Revenue This Year
- FUTU $48.73
- BIO N/A
- Revenue Next Year
- FUTU $9.97
- BIO $3.49
- P/E Ratio
- FUTU $20.28
- BIO N/A
- Revenue Growth
- FUTU 54.51
- BIO N/A
- 52 Week Low
- FUTU $51.80
- BIO $211.43
- 52 Week High
- FUTU $130.88
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- FUTU 58.15
- BIO 65.86
- Support Level
- FUTU $117.78
- BIO $237.42
- Resistance Level
- FUTU $126.00
- BIO $254.82
- Average True Range (ATR)
- FUTU 4.97
- BIO 7.14
- MACD
- FUTU -0.06
- BIO 2.35
- Stochastic Oscillator
- FUTU 67.97
- BIO 89.82
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.